Real-world outcomes following 15 years of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration
- Journal
- Eye (London, England) (Q1)
- Published
- 15 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Long T Phan, Geoffrey K Broadhead, Kimberly L Spooner, Samantha Fraser-Bell, James G Wong, Thomas H Hong, et al.
- PMID
- 43035550
- DOI
- 10.1038/s41433-026-04933-z
Why clinicians should know about it
- Picked for Ophthalmology (paper of the day, 18 November 2026): Fifteen-year real-world visual outcomes after anti-VEGF for neovascular AMD
Abstract
BACKGROUND/OBJECTIVES: To evaluate visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy over 15-years in a real-world setting. SUBJECTS/METHODS: A retrospective cohort study was conducted. Eyes with nAMD that began ranibizumab treatment between 2006 and 2009 were assessed for eligibility which required ≥ 15 years of continuous follow-up, and no prior photodynamic therapy or earlier anti-VEGF use. A total of 1202 eyes were evaluated, of which 107 met the eligibility criteria. Medical records and corresponding optical coherence tomography scans were evaluated to assess changes from baseline in visual acuity (VA), central macular thickness (CMT), anatomic findings, injection frequency, and adverse events. RESULTS: Mean age was 69 ± 8.7 years and mean VA was 58.4 ± 16.6 letters at treatment initiation. At year 15, mean VA change from baseline was -8.5 letters (p < 0.001, 95% CI -13.4 to -3.6). The proportion of eyes with VA 20/40 or better was 32%, and the proportion of eyes with VA worse than or equal to 20/200 was 31%. Subretinal fibrosis was present in 43% of eyes, and macular atrophy was present in 74% of eyes, 67% of which were sub-foveal. Subretinal fibrosis, sub-foveal macular atrophy, and treatment discontinuation were each associated with final VA in multivariate analysis. CONCLUSIONS: Anti-VEGF therapy was associated with early anatomical improvements and long-term visual preservation in a meaningful proportion of eyes with nAMD over 15 years. Macular atrophy and fibrosis were strongly associated with poorer visual outcomes.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.